Publications of interest suggested by our medical advisory group, updated bimonthly

• Ludwig D.S., MD et al., Physiological mechanisms relating to obesity, diabetes, and cardiovascular disease, JAMA, 2002, vol. 287, 2414-2423 www.jama.com 6/02
• Gillis L.J. et al., Relationship between juvenile obesity, dietary energy fat intake and physical activity, Int. J. of Obesity, 2002, 26, 458-463 6/02
• Meyers S.P., Ph.D. et al., Antibacterial activity of chitosans and chitosan oligomers with different molecular weights, Int. J. of Food Microbiology, March 2002, vol. 74, No. 1-2, 65-72  6/02
• Tamai Y., Ph.D. et al., Enhanced healing of cartilaginous injuries by glucosamine hydrochloride, Carbohydrate Polymers, 2002, vol. 48, 369-378 6/02
• Glazer G., MD, Long-term pharmacotherapy of obesity, a review of efficacy and safety, Arch. Intern Med., 2001, vol. 161, 1814-1824 6/02
• S. Y. Yanovski, MD et al., Obesity, N. Engl. J Med., February 2002, vol. 346, No. 8, www.nejm.org
• M. Ishihara, Ph.D. et al., Photocrosslinkable chitosan as a dressing for wound occlusion and accelerator in healing process, Biomaterials, February 2002, vol. 23, 833-840.
• D.W. Kaufman, ScD et al, Recent patterns of medication use in the ambulatory adult population of the United States, The Slone survey, JAMA, 2002, vol. 287, 337-344 www.jama.com
• H. Ueno, MD et al, Topical fornulations and wound healing applications of chitosan, Advanced Drug Delivery Reviews, November 2001, vol. 52, 105-11
• K. L. Tucker, Ph.D. et al. Nutrition and aging in developing countries, J. Nutrition, 2001, vol. 131, 2417S-242
• M. Thanou, Ph.D. et al., Chitosan and its derivatives as intestinal absorption enhancers, Advanced Drug Delivery Reviews, October 2001, vol. 50, S91-S101
• J. Lee, MD, Glucosamine, Chondrotin Sulfate, and other alternative pharmacologic approaches to treating osteoarthritis, Phys. Med. & Rehab., vol 15, No. 1, February 2001  
• J.Y. Reginster, MD et al., Long term effects of Glucosamine Sulfate on osteoarthritis progression. A random, placebo-controlled clinical trial, The Lancet, vol. 357, January 2001
• P. Terry, MD et al., Fatty fish consumption and risk of prostate cancer, The Lancet, vol 357, June 2001
• A. Astrup, PhD. et al., The role of dietary fat in the prevention and treatment of obesity, Int. Jour. of Obesity, (2001) 25
• T.E. McAlindon, DM et al, Glucosamine and Chondroitin for treatment of osteoarthritis, JAMA, 2000, vol.283, 1469-1475
• B.G. Druss, MD, MOH et al. Association between use of unconventional therapies and conventional medical services, JAMA, 1999, vol.282, 651-656
• L.K. Han, PhD etc al., Reduction in fat storage during chitin-chitosan treatment in mice fed a high-fat diet, Int. Journal of Obesity, 1999, vol.23, 174-179
• R.A.A. Muzzarelli, PhD, Clinical and biological evaluation of Chitosan for hypercholestolemia and overweight control, Chitin and Chitosan, 1999
• R.Krishnedu, PhD, Oral gene delivery with Chitosan-DNA nanoparticles generates immunologic protection in murine model peanut allergy, Nature Medicine, 1999, vol 5, 316-386
• M.K. Serdula, MD, MPH etc al., Prevalencce of attempting weight loss and strategies for controlling weight JAMA, 1999, vol. 282, 1353-1358
• D. Steinberg, MD, PhD etc al., Preventing coronary artery disease by lowering cholestrol levels, JAMA, 1999, vol 282, 2043-2050
• E. Wuolijoki, PhD etc al, Decrease in serum LDL cholestrol with microcrystalline Chitosan, Find Exp. Clinical Pharmacol, 1999, vol 21, 357-361
• S.S. Koide, MD, PhD, Chitin-Chitosan: Properties, Benefits and Risks, Nutritional Research, 1998, vol 18, 1091-1101
• R.A.A. Muzzarelli, PhD, management of hypercholestrolemia and overweight by oral administration of chitosan, New biomedical Materials, Chapman, 1998, 135-142
• R. Sahelian, MD, Glucosamine, Nature’s Arthritis Remedy, 1997